Market Newsdesk

DALLAS, Nov. 24, 2020 /PRNewswire/ — Sunoco LP (NYSE: SUN) (“Sunoco”) today announced the early tender results for its previously announced cash tender offer (the “Offer”) for any and all of its outstanding 4.875% Senior Notes due 2023 (the “Notes”). The terms and conditions of the Offer are set forth in the Offer to Purchase, dated November 9, 2020, as amended to “upsize” the Offer and remove the tender cap (as the same may be further amended or supplemented, the “Offer to Purchase”). The Offer will expire at 11:59 p.m., New York City time, on December 8, 2020, unless extended or earlier terminated by Sunoco.

As of 5:00 p.m., New York City time, on November 23, 2020 (such time and date, the “Early Tender Deadline”), according to information provided by D.F. King & Co., Inc., the tender and information agent for the Offer, the aggregate principal amount of the Notes set forth in the table below under “Principal Amount Tendered at Early Tender Deadline” had been validly tendered and not validly withdrawn in the Offer. Withdrawal rights for the Notes expired at 5:00 p.m., New York City Time, on November 23, 2020.

The Total Consideration (as defined in the Offer to Purchase) for each $1,000 principal amount of Notes tendered and not validly withdrawn at or prior to the Early Tender Deadline and accepted for purchase pursuant to the Offer is $1,017.50. The Total Consideration includes the Early Tender Payment.

Only holders of Notes who validly tendered and did not validly withdraw their Notes at or prior to the Early Tender Deadline are eligible to receive the Total Consideration for the Notes accepted for purchase. In addition, holders whose Notes are purchased in the Offer will receive accrued and unpaid interest from the most recent interest payment date for the Notes to, but not including, the payment date.

It is anticipated that the payment date for the Notes validly tendered and accepted for purchase at or prior to the Early Tender Deadline will be November 24, 2020, subject to change without notice.

Sunoco’s obligation to accept for purchase and to pay for the Notes validly tendered and not validly withdrawn pursuant to the Offer is subject to the satisfaction or waiver, in Sunoco’s discretion, of certain conditions, which are more fully described in the Offer to Purchase. The complete terms and conditions of the Offer are set forth in the Offer to Purchase. Holders of the Notes are urged to read the Offer to Purchase carefully.

Credit Suisse Securities (USA) LLC and Barclays Capital Inc. are acting as lead dealer managers for the Offer. The tender agent and information agent for the Offer is D.F. King & Co., Inc. Questions regarding the Offer may be directed to Credit Suisse Securities (USA) LLC at (800) 820-1653 (Toll-free) or (212) 538-2417 or Barclays Capital Inc. at (800) 438-3242 (Toll-free) or (212) 528-7581. Holders who would like additional copies of the offer documents may call the information agent, D.F. King & Co., Inc. at (866) 796-6867 (Toll-Free) or (212) 269-5550, by email at [email protected].

This press release is for informational purposes only and does not constitute a notice of redemption under the optional redemption provisions of the indenture governing the 2023 notes, nor does it constitute an offer to sell, or a solicitation of an offer to buy any security, including the debt securities offered in the debt financing (the “new notes”), nor does it constitute a solicitation for an offer to purchase any security, including the new notes or the 2023 notes. The Offer is being made solely by means of the Offer to Purchase, which sets forth the complete terms and conditions of the Offer. The Offer is not being made to holders of 2023 notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

About Sunoco LP
Sunoco LP is a master limited partnership with core operations that include the distribution of motor fuel to approximately 10,000 convenience stores, independent dealers, commercial customers and distributors located in more than 30 states as well as refined product transportation and terminalling assets. SUN’s general partner is owned by Energy Transfer Operating, L.P., a wholly owned subsidiary of Energy Transfer LP (NYSE: ET).

Forward-Looking Statements

This news release may include certain statements concerning expectations for the future that are forward-looking statements as defined by federal law, including without limitation statements regarding the Offer and the concurrent debt financing. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that are difficult to predict and many of which are beyond management’s control. An extensive list of factors that can affect future results are discussed in Sunoco’s Annual Report on Form 10-K and other documents filed from time to time with the Securities and Exchange Commission. In addition to the risks and uncertainties previously disclosed, Sunoco has also been, or may in the future be, impacted by new or heightened risks related to the COVID-19 pandemic and the recent decline in commodity prices, and cannot predict the length and ultimate impact of those risks. Sunoco undertakes no obligation to update or revise any forward-looking statement to reflect new information or events.

The information contained in this press release is available on our website at www.SunocoLP.com

Contacts


Investors:

Scott Grischow, Vice President – Investor Relations and Treasury
(214) 840-5660, [email protected]

Derek Rabe, CFA, Manager – Investor Relations, Strategy and Growth
(214) 840-5553, [email protected]

Media:

Alexis Daniel, Manager – Communications
(214) 981-0739, [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/sunoco-lp-announces-early-tender-results-of-tender-offer-of-its-4-875-senior-notes-due-2023–301179630.html

SOURCE Sunoco LP

–Highest-accuracy portable inspection tool faster and easier to use–

LAKE MARY, Fla., Nov. 24, 2020  /PRNewswire/ — FARO^® Technologies, Inc. (Nasdaq: FARO), a global leader for 3D Metrology, AEC (Architecture, Engineering & Construction), and Public Safety Analytics, today announced its next generation Vantage Laser Tracker 6 Degrees of Freedom (6DoF) Probe. The new 6Probe offers exceptional portability and is compatible with FARO Vantage^S6 and Vantage^E6 Laser Trackers, enabling users to build, inspect and measure products faster and with greater accuracy.

The 6Probe is a cost-effective 6DoF solution that meets the dynamic measurement, speed, and accuracy requirements of the most challenging industrial applications. With kinematic self-identifying styli, users can now change probing tips quickly and measure without any recalibration and also measure hidden areas outside of the tracker’s line of sight, with wider acceptance angles. The result is an advanced tool upgrade designed to enhance productivity and efficiency. In fact, the typical user of the new 6Probe can now save at least 30 minutes of time on any given workday.

“The next generation Vantage Laser Tracker 6DoF Probe extends maximum measurement consistency and reliability in a variety of working environments, delivering best-in-class performance through faster and easier probing than previous models,” said Leo Martinez, FARO Product Marketing Manager. “With Super 6DoF and conventional 6DoF probing, FARO offers the industry’s most comprehensive 6DoF solutions available.”

6DoF and standard probing are enhanced by FARO ActiveSeek™, a feature to automatically locate and follow the active target. FARO trackers support the patented Super 6DoF TrackArm solution, which allows the Vantage and one or more FARO ScanArms to work together to create an integrated contact and noncontact 3D measurement system for large-volume measurement. With a range of up to 60 meters (with a 4-meter reach), Super 6DoF eliminates line-of-sight challenges and expands measurement range while maintaining superior accuracy.

The Vantage platforms offer comprehensive, large-volume 3D measurement up to 80 meters, significantly streamlining processes and reducing inspection cycle times while ensuring complete confidence in the results. The Laser Trackers maximize 6DoF measurement capabilities via the optional 6Probe, enabling precise measurement of hidden areas and small features.

For more information about FARO visit: www.faro.com.     

View original content to download multimedia:http://www.prnewswire.com/news-releases/faro-launches-latest-vantage-laser-tracker-6dof-probe-301179142.html

SOURCE FARO

SANTA CLARA, Calif., Nov. 24, 2020 /PRNewswire/ — Today eHealth, Inc. (NASDAQ: EHTH) (eHealth.com) released results from a new survey of more than 400 consumers enrolled in individual and family health insurance plans compliant with the Affordable Care Act (ACA). The survey was conducted in the midst of the ACA’s nationwide open enrollment period for 2021 coverage, which began November 1 and is scheduled to continmue through December 15, 2020.

Key findings from the survey:

• Nearly two thirds of ACA enrollees think the law needs to be revised: 64% feel the health reform law needs to be reworked to better serve consumers like themselves; 60% of those receiving federal subsidies to lower their premiums feel this way, as did 66% of those not receiving federal subsidies.

• Many express discomfort with the idea of getting a coronavirus vaccine this winter: 41% say they would feel either “very” or “somewhat” uncomfortable getting a new coronavirus vaccine this winter; Democratic voters are more likely than Republican voters to feel comfortable being immunized (66% vs. 51%).

• A strong majority support mandatory mask rules: 81% say masks should be required in public places where social distancing is difficult; 99% of likely Democratic voters favor mandatory mask rules, as do 64% of Republican voters.

• Many want access to non-standard coronavirus treatments: 41% want access to unproven or experimental treatments if they come down with the coronavirus.

• Democrats are much more likely to cite coronavirus as a major issue when voting this year: 46% of all voters say coronavirus was one of their top three issues when voting in this year’s presidential election; 69% of likely Democratic voters say it was one of their top three issues, compared to 24% of likely Republican voters.

Read the full survey report.

Findings presented in this report are based on a voluntary survey of individual and family health insurance plan enrollees who purchased ACA-compliant health insurance plans through eHealth. The survey was conducted between November 13 and 16, 2020, and a total of 415 responses were collected. Refer to the full survey report for additional methodology information.

About eHealth

eHealth, Inc. (NASDAQ: EHTH) operates a leading health insurance marketplace at eHealth.com and eHealthMedicare.com with technology that provides consumers with health insurance enrollment solutions. Since 1997, we have connected more than 8 million members with quality, affordable health insurance, Medicare options, and ancillary plans. Our proprietary marketplace offers Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other plans from over 180 health insurance carriers across fifty states and the District of Columbia.

Media inquiries:

Lara Sasken

Vice President, Corporate Communications
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/with-the-acas-open-enrollment-period-underway-ehealth-survey-explores-enrollees-sentiments-on-coronavirus-and-health-reform-301179621.html

SOURCE eHealth, Inc.

PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator^® electroporation or gene electrotransfer platform from IGEA Clinical Biophysics (“IGEA”). The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec’s visceral lesion applicator (VLA) program. Additionally, the U.S. Food and Drug Administration (FDA) has cleared the Cliniporator platform for use in the upcoming Phase 1 trial to be held at Providence Health investigating CORVax12, the Company’s DNA-encodable vaccine candidate for COVID-19. CORVax12 combines TAVO™ (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), with the National Institute of Health (NIH)’s SARS-CoV-2 virus “spike” protein.

“Based on our recently presented data at SITC and the current competitive landscape, we are confident that our gene electrotransfer technology will emerge as a preferred choice for therapeutic gene delivery in patients with advanced cancer for whom currently available treatment options have little or no effect,” said Daniel O’Connor, Chief Executive Officer of OncoSec. “The efficiency at which gene electrotransfer delivers therapy, along with a highly favorable safety profile and ease of use, make it an ideal choice for drug delivery. While our own current gene electrotransfer technology platform remains in development for low voltage applications, the exclusive rights we obtained under the IGEA Agreement provides OncoSec with the opportunity to bring low voltage technology to the clinic sooner, which potentially allows us to accelerate our VLA program. Low voltage application is also favorable for the delivery of DNA vaccines, and we will be testing Cliniporator in U.S. clinics as part of the Phase 1 clinical trial investigating CORVax12. Our unique approach with CORVax12 aims to produce stronger, longer-lasting immune responses and better protection against COVID-19 and other viruses, which is of particular importance for patient populations at risk of mounting an inadequate immune response, such as the elderly or immunocompromised individuals.”

The Cliniporator® is CE marked and can be used in most countries outside the United States and is routinely used for electrochemotherapy in and outside of Europe in over 200 major oncological centers to treat cutaneous metastatic cancer nodules, including melanoma. IGEA has clinical experience with gene therapy as well, which OncoSec will build on. This pioneering technology will strengthen OncoSec’s current product candidate portfolio and potentially provide an important accelerator to the Company’s upcoming clinical trials.

Ruggero Cadossi, M.D., IGEA President, added, “We are proud to collaborate with OncoSec, a company committed to delivering innovative therapies to cancer patients. The culture of knowledge, honesty, moral commitment and the focus on solutions for patients diagnosed with cancer and other life-threatening diseases were and will continue to be the guiding light of IGEA.”

About TAVO™
OncoSec’s gene therapy technology combines TAVO^TM (tavokinogene telseplasmid), a DNA plasmid-based interleukin-12 (IL-12), with an intra-tumoral electroporation gene delivery platform to achieve endogenous IL-12 production in the tumor microenvironment that enables the immune system to target and attack tumors throughout the body. TAVO™ has demonstrated a local and systemic anti-tumor response in several clinical trials, including the pivotal Phase 2b trial KEYNOTE-695 for metastatic melanoma and the KEYNOTE-895 Phase 2 trial in triple negative breast cancer (TNBC). TAVO™ has received Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration (FDA) for the treatment of metastatic melanoma following progression on KEYTRUDA® or OPDIVO®.

About Visceral Lesion Applicator (VLA) Program
OncoSec’s investigational visceral lesion applicator (VLA) technology is designed to treat non-cutaneous, internal tumors through direct delivery of OncoSec’s lead product candidate, TAVO™, or other immunologically relevant genes and immunotherapies. Lesions located within organs of the gastrointestinal tract, lung, liver, pancreas and bone can often be difficult to treat successfully with conventional therapies. This investigational, next-generation intratumoral delivery platform will be comprised of novel access applicators, both rigid and flexible catheter-based, as well as reversible, low-voltage electroporation generators, including Cliniporator ® and Oncosec’s technology in development, APOLLO.

About CORVax12
CORVax12 is the only DNA vaccine that uses an immune stimulant to promote an immune response against the SARS-CoV-2 virus. The CORVax12 vaccine approach combines the co-administration of TAVO™ (plasmid IL-12) with a DNA-encodable version of the SARS-CoV-2 spike or “S” glycoprotein to enhance immunogenicity of the component developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center. CORVax12 is designed to drive a coordinated vaccine response, capable of drawing upon the innate and adaptive humoral and cellular arms. This multi-pronged innate, adaptive and cellular immune response has the potential to generate a robust anti-viral response.

About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the “Company,” “OncoSec,” “we” or “our”) is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. OncoSec’s lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com. TAVO™ is a trademark of OncoSec Medical Incorporated.

TAVO™ is a trademark of OncoSec Medical Incorporated.

Risk Factors and Forward-Looking Statements
This release, as well as other information provided from time to time by the Company or its employees, may contain forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Forward-looking statements provide the Company’s current beliefs, expectations and intentions regarding future events and involve risks, uncertainties (some of which are beyond the Company’s control) and assumptions. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will” and “would” and similar expressions (including the negative of these terms). Although we believe that expectations reflected in the forward- looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The Company intends these forward-looking statements to speak only at the time they are published on or as otherwise specified, and does not undertake to update or revise these statements as more information becomes available, except as required under federal securities laws and the rules and regulations of the Securities Exchange Commission (“SEC”). In particular, you should be aware that the success and timing of our clinical trials, including safety and efficacy of our product candidates, patient accrual, unexpected or expected safety events, the impact of COVID-19 on the supply of our candidates or the initiation or completion of clinical trials and the usability of data generated from our trials may differ and may not meet our estimated timelines. Please refer to the risk factors and other cautionary statements provided in the Company’s Annual Report on Form 10-K for the fiscal year ended July 31, 2020 and subsequent periodic and current reports filed with the SEC (each of which can be found at the SEC’s website www.sec.gov), as well as other factors described from time to time in the Company’s filings with the SEC.

Company Contact

Keir Loiacono

Vice President, Corporate Development
+1-914-329-9071
[email protected]

Media Contact

Monica Rouco Molina, Ph.D.
LifeSci Communications
+1-929-469-3850
[email protected]

View original content:http://www.prnewswire.com/news-releases/oncosec-announces-exclusive-license-agreement-for-cliniporator-gene-electrotransfer-platform-developed-by-igea-clinical-biophysics-301179764.html

SOURCE OncoSec Medical Incorporated

Latest Strategic Milestones Include: Company Overview Presentation, Multi-Warehouse Shipping Solution with NRI Distribution and Re-Launch of North American Wholesale Division.

VANCOUVER, BC, Nov. 24, 2020 /PRNewswire/ – RYU Apparel Inc. (TSXV: RYU) (OTC: RYPPF) (FWB: RYAA) (“RYU” or the “Company“), a creator of award-winning urban athletic apparel, is pleased to share a second corporate update letter from CEO Cesare Fazari.

Dear Shareholders,

In my first CEO letter I made the commitment that we would be consistent in sharing updates on our operational progress with investors. In my previous CEO update I outlined the details of our Phase I corporate initiatives.  Our rapid progress continues, and I’m again delighted to share three key updates from Phase II of our corporate strategy.

1. RYU has deployed a new multi-warehouse shipping solution that makes Canadian inventory available to customers across the United States. RYU’s zone skipping based solution consolidates shipments, decreases delivery times and reduces costs while minimizing likelihood of delays for individual shipments. Further, RYU’s ShopifyPlus direct to warehouse integration is on track for completion prior to close of Q4 2020. Furthering the company’s commitment to a “Digital First” ecommerce infrastructure, these activations augment our global partnership with Afterpay (ASX: APT), the leader in “Buy Now, Pay Later” payments, as well as the changeover of our Ecommerce store to the Shopify (TSE: SHOP) platform. 
2. As part of our omni channel strategy, I’m also incredibly pleased to welcome Grant Matzen to the RYU family. Mr. Matzen will be in charge of the re-launch and scaling of RYU’s North American wholesale division. Mr. Matzen is an experienced sales and marketing professional with over a decade of experience working with iconic brands in the sports and lifestyle apparel industry such as Under Armour (NYSE: UAA), Vans, Quiksilver, and Roxy. Most recently, Mr. Matzen worked with Stormtech Performance Apparel as Sales Manager – Retail and International, where he developed a complete wholesale division, building out the sales team and strategy for taking the brand to the retail market. Said Mr. Matzen, “I’m extremely excited to be joining the RYU team as it has been a brand I have admired for years. Their high-end product, message of respect, and the team in place is inspiring to be part of. I see amazing things for the future of RYU.”
3. Lastly, for those new or familiar with our story I welcome you to review our latest Corporate Overview Presentation. I’m not shy about my belief in the power of the RYU brand, quality of our products and I trust this presentation will give credence to who we are, why we do what do and our vision of success.

In summary, our significant progress is the result of a clear strategy alongside diligent execution and work ethic from our team.  These efforts and your ongoing support continue to progress RYU towards being a dominant industry force.

As always, I thank RYU’s shareholders for your support throughout this process and for your belief in our vision.

Sincerely,
Cesare Fazari
CEO
RYU

About RYU Apparel

RYU Apparel (TSXV: RYU, PINK: RYPPF, FWB: RYAA), or Respect Your Universe, is an award winning urban athletic apparel and accessories brand engineered for the fitness, performance and lifestyle of the athletic man and woman. Designed without compromise for fit, comfort, and durability, RYU exists to facilitate optimal human performance. For more information, please visit the RYU website at: http://ryu.com 

Forward Looking Statements Disclaimer

Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange Inc.) accepts responsibility for the adequacy or accuracy of this press release.

This news release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of RYU, such as statements the renewal of the RYU brand, implementation of strategic objectives and regaining profitability of RYU in 2021; revenue projections for Q3 and Q4 more than doubling from 2019; increasing the RYU footprint in Canada and U.S. and RYU becoming a dominant industry force; entering into a consulting relationship with Joel Primus, co-founder of Naked Brands Inc.; changes in operations resulting
cost saving and other advantages;
planned reopening of our flagship store which will pilot the “RYU Studio” concept.
There are numerous risks and uncertainties that could cause actual results and RYU’s plans and objectives to differ materially from those expressed in the forward-looking information, including:
(i
) adverse market conditions, including conditions arising as a result of the COVID-19 pandemic or otherwise; (ii) an inability to renew the RYU brand, implement strategic objectives and regain profitability; (iii) failing to meet target revenue projections as anticipated; (iv) failing to enter into the anticipated consulting arrangement and (v) the inability to complete the planned re-opening of the its store or the piloting of the “RYU Studio” concept. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking statements are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, RYU does not intend to update these forward-looking statements. 

View original content:http://www.prnewswire.com/news-releases/ryu-apparel-inc-ceo-shares-three-key-corporate-updates-301179766.html

SOURCE RYU Apparel Inc.

BEIJING, Nov. 24, 2020 /PRNewswire/ — WiMi Hologram Cloud Inc. (Nasdaq: WIMI) (“WiMi” or the “Company”), a leading augmented reality (“AR”) service provider in China, today announced that a new product of Hologram head-mounted display (” head-mounted display “), ” WiMi Hologram Soft Light “, has been licensed by the FCC to enter the US market. The certification document shows that the head-mounted display model WMH0D3 has been certified by the FCC through appearance, data transmission, product radiation and other tests. The document includes pictures, user manual and RF reports.

FCC certification is a certification issued by the Federal Communications Commission for electronic products. Many radio application products, communications products and digital products to enter the United States market, require FCC approval.

Recognizing the growing demand of customers for quality Hologram head-mounted display products, the Company has leveraged its cutting-edge technical capabilities to design the “WiMi Hologram Soft Light” (the “Product“). The Company plans to launch the Product by the end of 2020. The Product will feature a number of state-of-the-art upgrades related to image color management, wearing experience, and device compatibility. The Company has cooperated with SONY to integrate a powerful image processing engine into the Product, allowing it to display colors vividly and provide its users with a higher picture quality. At the same time, the Company has alsointegrated infinity focus imaging technology into the Product to reduce user fatigue, which is commonly caused by the continual use of Hologram head-mounted display products as well as extended periods of time spent focusing on screens at close proximity, thus greatly improving the customer’s wearing experience. In terms of device compatibility, the Product will support connection with several types of drones and professional cameras.

About WIMI Hologram Cloud Inc.

WiMi Hologram Cloud, Inc.(NASDAQ: WIMI), whose commercial operations began in 2015, operates an integrated holographic AR application platform in China and has built a comprehensive and diversified holographic AR content library among all holographic AR solution providers in China. Its extensive portfolio includes 4,654 AR holographic contents. The company has also achieved a speed of image processing that is 80 percent faster than the industry average. While most peer companies may identify and capture 40 to 50 blocks of image data within a specific space unit, WiMi collects 500 to 550 data blocks.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release, as well as the Company’s strategic and operational plans, contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the U.S. Securities and Exchange Commission (“SEC”) on Forms 20−F and 6−K, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company’s goals and strategies; the Company’s future business development, financial condition and results of operations; the expected growth of the AR holographic industry; and the Company’s expectations regarding demand for and market acceptance of its products and services. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable laws. 

View original content:http://www.prnewswire.com/news-releases/wimi-announced-that-the-hologram-product–wimi-hologram-soft-light–has-been-approved-by-the-fcc-to-enter-the-us-market-301179586.html

SOURCE WiMi Hologram Cloud Inc.

HOUSTON, Nov. 24, 2020 /PRNewswire/ — Luby’s, Inc. (NYSE: LUB) (“Luby’s” or the “Company”), – Just in time for the holiday rush, Luby’s is offering a homebound solution for fans of its fresh, home-style fare. The landmark cafeteria chain’s Holiday Meal Packages are designed to make catering home and office celebrations a snap.

Holiday Thanksgiving Packages are still available; contact your local Luby’s Cafeteria to place orders. In addition, 60 Luby’s Cafeterias will be open and serving guests on Thanksgiving Day from 11:00 a.m. to 7:00 p.m. Central.

Todd Coutee, Luby’s Chief Operating Officer commented, “While our guest and employees have all been working hard to manage through the global pandemic since March, at Luby’s two primary principles remain unchanged – delighting our guests with great service and providing delicious food offerings. We’ve been serving guests based on these two core beliefs for decades. Our restaurant teams have not altered their commitment to impeccable guest service and providing high-quality, flavorful food for legions of loyal guests. Building a strong team and preparing for our stellar Holiday Meal Packages has been nothing but seamless! Regardless of where families are gathering this year for Thanksgiving or Christmas, Luby’s is ready to serve your family and provide our signature holiday packages.”

Christmas offerings include Holiday Packaged Meals – last day to order for Christmas will be December 21 and pickup will be December 23.  In addition, Luby’s offers great Christmas gift items, the Luby’s Cookbook for $35 and Luby’s Gift Cards, both available for in-store purchase only.  

About Luby’s

Luby’s, Inc. (NYSE: LUB) operates two core restaurant brands: Luby’s Cafeterias and Fuddruckers. Luby’s is also the franchisor for the Fuddruckers restaurant brand. In addition, through its Luby’s Culinary Contract Services business segment, Luby’s provides food service management to sites consisting of healthcare, corporate dining locations, sports stadiums, and sales through retail grocery stores.

For additional information contact:

Dennard Lascar Investor Relations
Rick Black / Ken Dennard
[email protected]

View original content:http://www.prnewswire.com/news-releases/lubys-holiday-offerings-301179759.html

SOURCE Luby’s, Inc.